🆕 Updated 2021 ACR Guidance for Adjusting Immunomodulatory Therapy with the COVID-19 Vaccine in Patients with Rheumatic & MSK Diseases Discussed at #ACR21 COVID-19 Hub! V4 Link: https://t.co/1SOR9yTQyF https://t.co/PKFKXpLofN

• https://tinyurl.com/c19vaxv4

#ACR21 Year In Review: Factors associated with #COVID deaths in pts with #RMD: ⛔️age, male, HTN/CVD, lung disease, steroid>10mg/d, ⬆️disease activity ⛔️RTX (OR: 4), SFZ (3.6), other IS (2.2), No DMARDs (2.1) vs MTX monotherapy as reference @RheumNow https://t.co/Zd6qXCtGLk https://t.co/YHBEelLqKB

• https://bit.ly/3GVBZE0

Meta-analysis from @rheum_covid with @HsiehEvelyn shows that people with rheumatic disease are at⬆️risk of SARS-CoV-2 infection and⬆️mortality from COVID-19. Abstr#0086 #ACR21 @RheumNow #ACRBest https://t.co/B7tWs02gfc

Dr Patel @jeffsparks @zach_wallace_md comparative cohort study on CD-20 inhibitors and COVID. ⬆️ mortality, aHR 2.16 . Abstr#0085 #ACR21 @RheumNow https://t.co/wyfEBWurRi

Important differences between vascular pathologies seen in #COVID19 and DIC by Dr. D McGonagle 👉Fibrinogen - normal/sl. ⬆ in PIC-assoc'd COVID19 vs. ⬇ in DIC sec to MAS @RheumNow #ACR21 #MedTwitter 📌https://t.co/DdmAhVIR51 https://t.co/Xw8LKaKcFd

• DEFINE_ME

CARRA survey in SAID pts reported no change in flare frequency w/ COVID19 but many had reduced intensity of fevers during flares. Majority of pts reported mild to moderate symptoms w/ 1/3 had lingering COVID19 symptoms. Abs 1083 #RheumNow #ACR21 @RheumNow https://t.co/qbfsqvXutt https://t.co/6u33VDIexY

• Outcomes of COVID-19 Illness in Systemic Autoinflammatory Diseases and Changes …

"CH COVID-19: Office Hours: COVID-19 Vaccine in Immune-mediated Inflammatory Disease (IMID) Patients" #ACR21 A great thing about @ACRheum's Convergence is being able to listen to conversations about important topics like booster type & timing specifically for #rhum patients https://t.co/horwWeAen7